News Image

Investors should take notice of NASDAQ:PCRX—it offers a great deal for the fundamentals it presents.

By Mill Chart

Last update: Nov 29, 2023

Discover PACIRA BIOSCIENCES INC (NASDAQ:PCRX), an undervalued stock highlighted by our stock screener. NASDAQ:PCRX showcases solid financial health and profitability while maintaining an appealing valuation. We'll explore the details.

How We Gauge Valuation for NASDAQ:PCRX

ChartMill assigns a Valuation Rating to every stock. This score ranges from 0 to 10 and evaluates the different valuation aspects and compares the price to earnings and cash flows, while taking into account profitability and growth. NASDAQ:PCRX scores a 9 out of 10:

  • The Price/Earnings ratio is 9.72, which indicates a very decent valuation of PCRX.
  • Based on the Price/Earnings ratio, PCRX is valued cheaper than 89.27% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of PCRX to the average of the S&P500 Index (24.46), we can say PCRX is valued rather cheaply.
  • A Price/Forward Earnings ratio of 6.96 indicates a rather cheap valuation of PCRX.
  • Based on the Price/Forward Earnings ratio, PCRX is valued cheaper than 92.20% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 19.59. PCRX is valued rather cheaply when compared to this.
  • Based on the Enterprise Value to EBITDA ratio, PCRX is valued cheaper than 87.32% of the companies in the same industry.
  • 91.71% of the companies in the same industry are more expensive than PCRX, based on the Price/Free Cash Flow ratio.
  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • PCRX has a very decent profitability rating, which may justify a higher PE ratio.
  • PCRX's earnings are expected to grow with 25.60% in the coming years. This may justify a more expensive valuation.

Looking at the Profitability

ChartMill's Profitability Rating offers a unique perspective on stock analysis, providing scores from 0 to 10. These ratings consider a wide range of profitability metrics and margins, both in comparison to industry peers and on their own merits. For NASDAQ:PCRX, the assigned 7 is a significant indicator of profitability:

  • Looking at the Return On Assets, with a value of 0.46%, PCRX belongs to the top of the industry, outperforming 81.46% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 0.85%, PCRX belongs to the top of the industry, outperforming 81.95% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 3.49%, PCRX belongs to the top of the industry, outperforming 81.95% of the companies in the same industry.
  • PCRX has a Profit Margin of 1.07%. This is amongst the best in the industry. PCRX outperforms 81.95% of its industry peers.
  • The Operating Margin of PCRX (10.15%) is better than 82.93% of its industry peers.
  • PCRX's Operating Margin has improved in the last couple of years.
  • PCRX has a Gross Margin of 70.12%. This is in the better half of the industry: PCRX outperforms 78.05% of its industry peers.

What does the Health looks like for NASDAQ:PCRX

ChartMill utilizes a Health Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of liquidity and solvency ratios, both in absolute terms and in comparison to industry peers. NASDAQ:PCRX has earned a 6 out of 10:

  • PCRX's Altman-Z score of 1.83 is fine compared to the rest of the industry. PCRX outperforms 69.27% of its industry peers.
  • PCRX has a better Debt to FCF ratio (4.03) than 88.29% of its industry peers.
  • PCRX has a Current Ratio of 4.77. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
  • PCRX's Current ratio of 4.77 is fine compared to the rest of the industry. PCRX outperforms 62.44% of its industry peers.
  • A Quick Ratio of 3.74 indicates that PCRX has no problem at all paying its short term obligations.

Growth Examination for NASDAQ:PCRX

ChartMill assigns a Growth Rating to each stock, ranging from 0 to 10. This rating is determined by analyzing different growth elements, including EPS and revenue growth, spanning both historical and future figures. In the case of NASDAQ:PCRX, the assigned 5 reflects its growth potential:

  • PCRX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 68.62% yearly.
  • PCRX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.40% yearly.
  • Based on estimates for the next years, PCRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.89% on average per year.

Our Decent Value screener lists more Decent Value stocks and is updated daily.

Our latest full fundamental report of PCRX contains the most current fundamental analsysis.

Keep in mind

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

PACIRA BIOSCIENCES INC

NASDAQ:PCRX (2/23/2024, 10:38:48 AM)

30.085

+0.12 (+0.38%)

PCRX News

News Imagea day ago - Pacira BioSciencesPacira to Report 2023 Financial Results on Thursday February 29, 2024
News Image8 days ago - Pacira BioSciencesPacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy
News Image8 days ago - Pacira BioSciencesPacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy

– Findings demonstrate significant reduction in pain and opioid consumption through 96 hours versus active comparator – – Significantly greater...

News Image14 days ago - ChartmillNASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

PACIRA BIOSCIENCES INC (NASDAQ:PCRX) appears to be flying under the radar despite its strong fundamentals.

News Image15 days ago - Market News VideoRSI Alert: Pacira BioSciences (PCRX) Now Oversold
News Image16 days ago - Pacira BioSciencesPacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.
News Image22 days ago - G.O.A.T. PaddleG.O.A.T. Bowl I Registration Open to 4 Additional Pickleball Teams

/PRNewswire/ -- Paradise PB Events and G.O.A.T. Paddle, the high performance pickleball company created by and for top players and those who want to compete...

News Image2 months ago - Pacira BioSciencesPacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues
News Image2 months ago - Pacira BioSciencesPacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues

TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain...

News Image2 months ago - Market News VideoNotable Wednesday Option Activity: PLCE, PCRX, SYY
News Image2 months ago - Pacira BioSciencesPacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
News Image2 months ago - Pacira BioSciencesPacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

TAMPA, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 42nd Annual J.P....

PCRX Links
Follow us for more